Mumbai: Pharmaceutical giants Cipla and Alkem Laboratories are in the final stages of a bidding war to acquire a controlling ...

Promoters of SMT—the Kotadia family— plan to keep a minority stake after the transaction that would see other shareholders ...

Alkem Laboratories Ltd., incorporated in the year 1973, is a Large Cap company (having a market cap of Rs 72,014.00 Crore) operating in Pharmaceuticals sector. Alkem Laboratories Ltd. key ...

India's largest stent manufacturer, Sahajanand Medical Technologies is also reportedly exploring a public listing on the domestic market ...

Alkem Laboratories partners with Sonnet BioTherapeutics to develop and commercialize SON-080, a potential treatment for ...

Under the licensing agreement, Alkem will carry out the clinical development of 'SON-080' in India with support from Sonnet ...

Mumbai: Alkem Laboratories Ltd. has entered into a licensing agreement with US-based Sonnet BioTherapeutics Holdings, Inc to ...

India is grappling with a substantial burden of diabetes-related complications with diabetic peripheral neuropathy being a ...

Alkem Laboratories said that it has entered into a licensing agreement with US-based Sonnet BioTherapeutics Holdings, to develop, manufacture and commercialise the drug candidate 'SON-080' for the ...

The drug is expected to offer nerve regeneration, potentially modifying the disease in diabetic peripheral neuropathy ...

新泽西州普林斯顿 - 临床阶段生物技术公司Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN)已与Alkem Laboratories Limited签订许可协议，在印度开发和商业化SON-080。SON-080是一种重组人白细胞介素-6(rhIL-6)，旨在治疗糖尿病周围神经病变(DPN)、化疗引起的神经病变(CIPN)和自主神经病变。 根据协议 ...